Celgene Faces Accusation of Reverse Domain Name Hijacking in CellGene.com Dispute

In a notable decision highlighting the complexities of domain name disputes, Celgene Corporation (NASDAQ: CELG), a prominent biopharmaceutical company, found itself on the receiving end of accusations of reverse domain name hijacking. A three-member panel from the World Intellectual Property Organization (WIPO) concluded that Celgene attempted to unfairly acquire the domain name CellGene.com, leading to significant implications for brand protection and domain name acquisition strategies.

The Genesis of the Dispute: Celgene’s Pursuit of CellGene.com

The dispute arose from Celgene’s attempt to purchase the domain name CellGene.com in 2018, a full 15 years after its initial registration. Celgene, acting through an intermediary, initiated contact with the domain name owner, expressing interest in acquiring the asset. The domain owner responded with a counteroffer of $7,500, setting the stage for a legal battle that would ultimately question Celgene’s intentions and practices in domain name acquisition.

WIPO Panel’s Ruling: No Legitimate Rights or Bad Faith Registration Proven

After careful consideration of the evidence presented, the WIPO panel ruled against Celgene. The panel determined that Celgene failed to demonstrate that the domain name owner lacked legitimate rights or interests in the domain name. Furthermore, the panel found no evidence to support the claim that the domain name was registered in bad faith. This determination formed the basis for the reverse domain name hijacking accusation against Celgene.

The Core of the Accusation: Misleading the Panel

The WIPO panel’s decision to accuse Celgene of reverse domain name hijacking stemmed from the belief that Celgene attempted to mislead the panel during the proceedings. The panel highlighted inconsistencies and omissions in Celgene’s presentation of the facts, particularly concerning the negotiation process and the initial offer made for the domain name.

The panel’s detailed findings revealed concerns about Celgene’s conduct:

“…In the Panel’s view, however, there is a more significant issue in the present case, which is that the Complainant has sought to mislead the Panel in accordance with item (iv) in the fourth paragraph of 4.16.”

The panel elaborated on this point, stating, “The Complainant claims that it offered the Respondent USD 2,000 for the disputed domain name when it became aware that the Respondent was listing it for sale in September 2018, that the Respondent counteroffered USD 7,500, which was ‘much more than what the domain should be sold for’ and that it was highly likely that the Respondent significantly increased the price when it discovered that the Complainant was interested in the disputed domain name. As mentioned above, the Complainant invoked this counteroffer by the Respondent as evidence that the Respondent registered the disputed domain name in bad faith for the purpose of sale to the Complainant under paragraph 4(b)(i) of the Policy.”

The panel emphasized the importance of transparency, stating, “In those circumstances, it was incumbent on the Complainant to produce all relevant communications relating to the counteroffer; but it did not do so. The emails included in the factual summary in section 4 above only came to the attention of the Panel at the behest of the Respondent.”

Further investigation revealed discrepancies in the timeline of events. “Even these emails do not appear to tell the full story, as they include no reference to the initial USD 2,000 offer mentioned by the Complainant. The Panel therefore deduces that this initial offer was made through the Respondent’s website and that, perhaps having received no or an unsatisfactory response, the decision was taken to follow up with the enquiry email of September 11, 2011. Crucially, this email was sent in the name of CSC. It made no mention of the Complainant and indeed gave no indication that CSC was acting for a client rather than on its own behalf (‘We are interested in purchasing…’). Thereafter, the Respondent’s broker responded with the counteroffer of USD 7,500.”

The panel concluded, “Accordingly, the communications appear to contradict the Complainant’s version of events and to confirm the Respondent’s assertion that the Complainant never revealed itself in the course of the purchase enquiries. In these circumstances, it is difficult to see how the Complainant can persuasively claim not only that the counteroffer indicated that the Respondent registered the disputed domain name for the purpose of sale to the Complainant but that the Respondent specifically increased its asking price to USD 7,500 when it allegedly discovered that the Complainant was interested in the disputed domain name.”

Understanding Reverse Domain Name Hijacking

Reverse domain name hijacking (RDNH) occurs when a trademark holder attempts to unfairly wrest a domain name from its legitimate owner. This typically involves using legal processes, such as WIPO arbitration, to claim ownership of a domain name based on trademark rights, even when the domain name was registered in good faith before the trademark was established or is being used for legitimate purposes unrelated to the trademark.

The WIPO’s Uniform Domain Name Dispute Resolution Policy (UDRP) is designed to prevent cybersquatting, where individuals register domain names that are identical or confusingly similar to trademarks with the intent of profiting from the trademark owner’s reputation. However, the UDRP can be misused by trademark holders to attempt to acquire domain names that they do not legitimately deserve, leading to RDNH.

Factors considered in RDNH cases include:

• Whether the domain name was registered and used in good faith.
• Whether the domain name owner has legitimate rights or interests in the domain name.
• Whether the trademark holder has attempted to mislead the dispute resolution panel.

Celgene’s Background and Acquisition by Bristol-Meyers Squibb

Celgene, at the time of the dispute, was a leading biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for the treatment of cancer and other serious diseases. Subsequently, Celgene was acquired by Bristol-Meyers Squibb, a global pharmaceutical company with a similar focus on developing and delivering innovative medicines.

The acquisition of Celgene by Bristol-Meyers Squibb further underscores the importance of brand protection and intellectual property rights in the biopharmaceutical industry. Domain names, as key components of online identity and brand recognition, are valuable assets that require careful management and protection.

Legal Representation

Celgene was represented by Cozen O’Connor, a prominent law firm known for its expertise in intellectual property law. The domain name owner was represented by ESQwire.com, a specialized law firm focusing on domain name disputes and intellectual property matters.

Implications and Lessons Learned

The Celgene case serves as a cautionary tale for companies pursuing domain name acquisitions. It highlights the importance of transparency, ethical conduct, and a thorough understanding of domain name dispute resolution processes. Companies should ensure that their actions are consistent with established legal principles and avoid any appearance of attempting to mislead dispute resolution panels.

Furthermore, the case underscores the need for companies to conduct comprehensive trademark searches and domain name registration strategies to protect their brands and prevent potential disputes. Proactive measures can help companies avoid costly legal battles and maintain control over their online presence.

For domain name owners, the Celgene case reinforces the importance of documenting legitimate rights and interests in their domain names. Maintaining records of registration dates, website content, and business activities can help demonstrate good faith use and defend against unwarranted claims of cybersquatting or reverse domain name hijacking.

The Importance of Proactive Brand Protection

In today’s digital landscape, a strong online presence is crucial for business success. This includes securing relevant domain names that align with a company’s brand and offerings. A proactive brand protection strategy involves:

• Trademark Registration: Registering trademarks in relevant jurisdictions to establish legal rights.
• Domain Name Registration: Registering domain names that are identical or similar to trademarks, including various top-level domains (TLDs) such as .com, .net, .org, and country-code TLDs (ccTLDs).
• Domain Name Monitoring: Continuously monitoring the internet for unauthorized use of trademarks in domain names.
• Enforcement Actions: Taking legal action against cybersquatters and others who infringe on trademark rights.
• Negotiation and Acquisition: When necessary, negotiating with domain name owners to acquire domain names that are important for brand protection.

Conclusion: A Reminder of Ethical Domain Acquisition Practices

The Celgene reverse domain name hijacking case serves as a valuable reminder of the importance of ethical and transparent domain acquisition practices. Companies must exercise caution and avoid actions that could be perceived as misleading or unfair. By adhering to established legal principles and prioritizing good faith conduct, companies can protect their brands and avoid costly legal disputes.

The case also highlights the critical role of the WIPO and other dispute resolution bodies in ensuring fairness and balance in domain name disputes. These organizations provide a forum for resolving conflicts and protecting the rights of both trademark holders and domain name owners.

Ultimately, the Celgene case underscores the need for a proactive and responsible approach to domain name management, one that prioritizes brand protection, ethical conduct, and respect for the rights of others.